Selank
Tuftsin analogue
Selank is a synthetic peptide with limited clinical research into anxiety symptoms. Current evidence does not reliably establish broad benefit or long-term safety.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
Selank is a tuftsin-related heptapeptide. Free base, acetate and N-acetylated market variants cannot be equated without exact specifications.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
Selank is a tuftsin-related heptapeptide. Free base, acetate and N-acetylated market variants cannot be equated without exact specifications.
- Human research
- Very limited
- Replication
- Single research group
- Clinical endpoints
- Symptom- or function-related
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Research gaps
- ·Limited human studies with little independent confirmation
- ·Dose and procedure are not fully documented in the accessible abstract
- ·Insufficient safety information according to FDA
Mechanism
An anxiolytic effect has been investigated. The clinically relevant mechanism is not settled by the human sources reviewed here.
- Selank in anxiety and somatoform disorders: comparative clinical studyHuman study2014
U.S. National Library of Medicine (PubMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Safety of the specific Selank form is inadequately established, including potential immune reactions.
Contraindications and warnings
- ·Contraindications for this use cannot be reliably determined from the available data.
Interactions
- ·Interactions for the research or product forms described here have not been adequately studied.
Research gaps
- ·Limited human studies with little independent confirmation
- ·Dose and procedure are not fully documented in the accessible abstract
- ·Insufficient safety information according to FDA
- FDA: Selank safety information in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- Selank in anxiety and somatoform disorders: comparative clinical studyHuman study2014
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Selank safety information in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed: